Related Experiment Video
Updated: Aug 5, 2026

Breath Collection from Children for Disease Biomarker Discovery
Published on: February 14, 2019
Harnessing Exhaled Breath for Lung Cancer Early Detection-Results From the ExPeL Study
Danita Kasi Patel1, Leon D'Cruz2,3, Waqar Ahmed4
1Manchester Institute of Biotechnology (MIB), Department of Chemistry, University of Manchester, Manchester, UK.
Abstract:
Scalable, non-invasive tools are critically needed to improve early lung cancer detection and optimize primary care referral pathways. We evaluated Inflammacheck, a point-of-care device utilizing exhaled breath condensate (EBC) H2O2 and physiological parameters with machine learning for non-invasive lung cancer detection in a real-world screening population. Exhaled Hydrogen Peroxide for Early Lung Cancer Detection (ExPeL) study participants, from the UK Targeted Lung Health Check (TLHC) programme, included individuals with suspected lung cancer and low-risk ever-smoker controls. EBC was collected via Inflammacheck, measuring H2O2, end-tidal CO2, humidity, temperature, and exhalation flow rate. Multivariate analyses (PCA, LDA and Mahalanobis distance) assessed intrinsic group separation. SMOTE-balanced data trained supervised machine learning models (stacked and voting ensembles), which were then evaluated on held-out test sets. In parallel, untargeted LC-MS metabolomics was performed to identify discriminatory molecular features. Analyzing 34 participants with valid EBC data, 83% of cancer cases were early-stage (I-II), reflecting a screening population. Multivariate analysis clearly separated lung cancer and controls across PCA, LDA, and Mahalanobis mapping. The voting ensemble model achieved: Accuracy 85.7%, Sensitivity 80%, Specificity 100%, Precision (PPV) 100%, ROC-AUC 0.90 and MCC 0.73. Crucially, no false positives were identified. EBC variables revealed greater dispersion in cancer patients, reflecting physiological heterogeneity missed by univariate analysis. Untargeted metabolomics identified 2132 features, with four key metabolites yielding an AUC of 0.969 for cancer discrimination. Inflammacheck effectively distinguishes early-stage lung cancer via a rapid, non-invasive breath test, findings which are highly relevant for primary care and screening triage, where non-specific symptoms and low prevalence pose challenges.
More Related Videos
08:23Real-time Breath Analysis by Using Secondary Nanoelectrospray Ionization Coupled to High Resolution Mass Spectrometry
Published on: March 9, 2018
07:09Assessment of Pulmonary Capillary Blood Volume, Membrane Diffusing Capacity, and Intrapulmonary Arteriovenous Anastomoses During Exercise
Published on: February 20, 2017
Related Concept Videos
Assessment of Respiration
Subjective Assessment: Nurses interview the patient to gather information directly during the subjective assessment. It includes questions about the individual's medical history, medications, and symptoms, focusing on past respiratory conditions like asthma or COPD,...
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Assessment of Diffusion and Perfusion
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this principle...